Business
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children’s Applied Gene and Cell Therapy Center (“AGCTC”) as Lead Manufacturing Partner Appointed Andrew Fang, Ph.D., as Head of Business Development BRISBANE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced C
About this update from Tempest Therapeutics, Inc.
[{"type":"image","alt":"Tempest Therapeutics","displaySize":"","headline":null,"caption":"Tempest Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":276,"url":"https://media.zenfs.com/en/globenewswire.com/2867b6171c53d10d1562509e04b23e18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uJMh.dHEU6FeCJQqq.f7bQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM4Ng--/https://media.zenfs.com/en/globenewswire.com/2867b6171c53d10d1562509e04b23e18","width":300,"height":276},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/uJMh.dHEU6FeCJQqq.f7bQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM4Ng--/https://media.zenfs.com/en/globenewswire.com/2867b6171c53d10d1562509e04b23e18","width":300,"height":276}},"lazy":false},{"type":"text","content":"Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM)","length":148,"tagName":"p"},{"type":"text","content":"Announced Cincinnati Children’s Applied Gene and Cell Therapy Center (“AGCTC”) as Lead Manufacturing Partner","length":108,"tagName":"p"},{"type":"text","content":"Appointed Andrew Fang, Ph.D., as Head of Business Development","length":61,"tagName":"p"},{"type":"text","content":"BRISBANE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.","length":337,"tagName":"p"},{"type":"text","content":"“We made strong progress in the first quarter as we continued to execute across our lead program TPST-2003,” said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. “We advanced key activities supporting the planned initiation of our U.S. registrational study of TPST-2003 in patients with rrMM, including announcing our lead manufacturing partner AGCTC and taking delivery of the TPST-2003 lentiviral vector, a critical component in the manufacturing of TPST-2003. At the same time, we strengthened our ability to unlock value across our remaining portfolio with the appointment of Andrew Fang, Ph.D., as our Head of Business Development, whose focus on strategic partnerships, licensing and corporate transactions will help ...